Dysregulated immune responses in the context of IBD have been therapeutically targeted by biologicals (i.e. anti- tumor necrosis factor (TNF)-α), corticosteroids and thiopurines [2]. The gene discussed is TNF; the disease is inflammatory bowel disease.